ES2168436T3 - Ensayo para determinar la actividad de ciclooxigenasa 1. - Google Patents

Ensayo para determinar la actividad de ciclooxigenasa 1.

Info

Publication number
ES2168436T3
ES2168436T3 ES96201845T ES96201845T ES2168436T3 ES 2168436 T3 ES2168436 T3 ES 2168436T3 ES 96201845 T ES96201845 T ES 96201845T ES 96201845 T ES96201845 T ES 96201845T ES 2168436 T3 ES2168436 T3 ES 2168436T3
Authority
ES
Spain
Prior art keywords
cyclloxygenase
activity
test
sample
prostaglandina
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96201845T
Other languages
English (en)
Inventor
Wanda A Cromlish
Brian P Kennedy
Gary O'neill
Philip J Vickers
Elizabeth Wong
Joseph A Mancini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Merck Frosst Canada and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26744337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2168436(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Frosst Canada and Co filed Critical Merck Frosst Canada and Co
Application granted granted Critical
Publication of ES2168436T3 publication Critical patent/ES2168436T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/61—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving triglycerides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/99—Miscellaneous (1.14.99)
    • C12Y114/99001—Prostaglandin-endoperoxide synthase (1.14.99.1), i.e. cyclooxygenase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCION DESCRIBE UN ENSAYO PARA DETERMINAR LA ACTIVIDAD DE LA CICLOOXIGENASA-1 DE UNA MUESTRA, QUE INCLUYE LOS PASOS DE: (A) AÑADIR (1) UNA PREPARACION DE CELULA COX-1, (2) UNA MUESTRA, QUE INCLUYE UN INHIBIDOR DE LA CICLOOXIGENASA-1 PUTATIVO, Y (3) ACIDO ARAQUIDONICO; Y (B) DETERMINAR LA CANTIDAD DE PROSTAGLANDINA E{SUB,2} PRODUCIDA EN EL PASO (A).
ES96201845T 1992-12-22 1993-12-17 Ensayo para determinar la actividad de ciclooxigenasa 1. Expired - Lifetime ES2168436T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99476092A 1992-12-22 1992-12-22
US08/064,271 US5543297A (en) 1992-12-22 1993-05-06 Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity

Publications (1)

Publication Number Publication Date
ES2168436T3 true ES2168436T3 (es) 2002-06-16

Family

ID=26744337

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96201845T Expired - Lifetime ES2168436T3 (es) 1992-12-22 1993-12-17 Ensayo para determinar la actividad de ciclooxigenasa 1.
ES94902571T Expired - Lifetime ES2105611T3 (es) 1992-12-22 1993-12-17 Adnc de la ciclooxigenasa-2 humana y ensayo para evaluar la inhibicion de la cilooxigenasa-2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES94902571T Expired - Lifetime ES2105611T3 (es) 1992-12-22 1993-12-17 Adnc de la ciclooxigenasa-2 humana y ensayo para evaluar la inhibicion de la cilooxigenasa-2.

Country Status (12)

Country Link
US (2) US5543297A (es)
EP (3) EP1130110A3 (es)
JP (2) JP3608622B2 (es)
AT (2) ATE155811T1 (es)
AU (1) AU5690694A (es)
CA (1) CA2151231C (es)
DE (2) DE69331340T2 (es)
DK (1) DK0675964T3 (es)
ES (2) ES2168436T3 (es)
GR (1) GR3025111T3 (es)
HK (1) HK1027471A1 (es)
WO (1) WO1994014977A1 (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837479A (en) * 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
US6107087A (en) * 1993-09-27 2000-08-22 Merck Frosst Canada & Co. High level expression of human cyclooxygenase-2
CA2179168A1 (en) * 1993-12-17 1995-06-22 Douglas A. Kniss Antisense oligonucleotides to suppress eicosanoid formation
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
AT401061B (de) * 1995-01-26 1996-06-25 Hafslund Nycomed Pharma Benutzung einer menschlichen monozytenartigen zellinie zur identifikation und bestimmung von substanzen zur hemmung des menschlichen enzyms cyclooxygenase-2
AU6029396A (en) * 1995-06-07 1996-12-30 University Of Rochester Mammalian prostaglandin h synthase-2
JPH0977664A (ja) * 1995-09-13 1997-03-25 Yakult Honsha Co Ltd シクロオキシゲナーゼ−２特異的阻害剤及び抗炎症剤
EP0889724A1 (en) * 1996-02-27 1999-01-13 Rpms Technology Limited Cox-2 selective inhibitors for managing labour and uterine contractions
AT402936B (de) * 1996-05-29 1997-09-25 Nycomed Austria Gmbh Benutzung einer menschlichen zellinie zur identifikation und bestimmung von substanzen zur hemmung der induktion der expression des cyclooxygenase-2-genes
GB2319032A (en) * 1996-10-04 1998-05-13 Merck & Co Inc Crystals of human cyclooxygenase-2 (hCOX-2)
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
EP1138324A1 (en) * 1996-11-21 2001-10-04 The Mount Sinai School of Medicine of New York University Treatment of neurodegenerative conditions with nimesulide
US6200760B1 (en) * 1997-02-24 2001-03-13 Cornell Research Foundation, Inc. Method of screening agents as candidates for drugs or sources of drugs
WO1998039967A1 (en) * 1997-03-12 1998-09-17 The General Hospital Corporation A method for treating or preventing alzheimer's disease
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
JP4588215B2 (ja) 1998-06-24 2010-11-24 ユニバーシティー オブ ダンディー ポリペプチド、ポリヌクレオチド及びそれらの用途
JP2002528413A (ja) * 1998-10-23 2002-09-03 メルク フロスト カナダ アンド カンパニー Ｅ型プロスタグランジンリガンド及びｃｏｘ−２選択的阻害剤を含む配合剤及び使用方法
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
GB9827430D0 (en) * 1998-12-11 1999-02-03 Ludwig Inst Cancer Res Differential expression in primary breast cancer
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
WO2000077245A1 (en) * 1999-06-16 2000-12-21 Temple University - Of The Commonwealth System Of Higher Education Cell-based assay for screening cox-2 inhibitors
US6933128B1 (en) 1999-06-16 2005-08-23 Temple University-Of The Commonwealth System Of Higher Education Cell-based assay for screening cox-2 inhibitors
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AR025049A1 (es) * 1999-08-06 2002-11-06 Searle & Co Ciclooxigenasa-1 (cox-1) y ciclooxigenasa-2 (cox-2) caninas.
CN1235911C (zh) * 1999-08-09 2006-01-11 利思进药品公司 多细胞因子－抗体复合物
WO2001036489A2 (en) 1999-11-12 2001-05-25 Merck Patent Gmbh Erythropoietin forms with improved properties
AU784490B2 (en) * 1999-12-08 2006-04-13 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
JP2003523330A (ja) * 2000-02-04 2003-08-05 チルドレンズ・ホスピタル・リサーチ・ファウンデイション アテローム性動脈硬化症および関連疾患のための脂質加水分解治療
AU4314801A (en) 2000-02-11 2001-08-20 Lexigen Pharm Corp Enhancing the circulating half-life of antibody-based fusion proteins
AU7172901A (en) * 2000-06-29 2002-01-14 Lexigen Pharm Corp Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
AU5754701A (en) * 2000-07-13 2002-01-30 Pharmacia Corp Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2mediated disorders
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
AU2001284753B2 (en) 2000-08-07 2006-10-26 Vanderbilt University Detection of COX-2 activity and anandamide metabolites
AU2002239679A1 (en) * 2000-12-20 2002-07-01 The Regents Of The University Of California Rolling circle amplification detection of rna and dna
CA2433354A1 (en) * 2000-12-29 2002-07-25 Neogenesis Pharmaceuticals, Inc. Affinity selection-based screening of hydrophobic proteins
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PT1366067E (pt) 2001-03-07 2012-11-29 Merck Patent Gmbh Tecnologia de expressão para proteínas contendo uma unidade de anticorpo de isotipo híbrido
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
MXPA03009924A (es) * 2001-05-03 2004-01-29 Merck Patent Gmbh Anticuerpo recombinante especifico de tumor y uso del mismo.
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
AU2002340063B2 (en) * 2001-09-28 2007-05-10 Brigham Young University Novel cyclooxygenase variants and methods of use
ES2381025T3 (es) * 2001-12-04 2012-05-22 Merck Patent Gmbh Inmunocitocinas con selectividad modulada
DK2336359T3 (en) 2002-05-09 2016-05-30 Brigham & Womens Hospital 1L1RL-1 as cardiovascular disease marker
US7314709B2 (en) * 2002-08-06 2008-01-01 Vanderbilt University Compositions and methods for detecting and quantifying COX-2 activity by lipoamino acid metabolism
WO2004055056A1 (en) * 2002-12-17 2004-07-01 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
CA2536622C (en) 2003-08-29 2014-02-11 The Brigham And Women's Hospital, Inc. Inhibitors of cellular necrosis
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
KR20080016527A (ko) * 2005-01-31 2008-02-21 밀란 래보러토리즈, 인크. 하이드록시화된 네비볼롤을 함유하는 약학적 조성물
US7358237B2 (en) * 2005-04-28 2008-04-15 The Johns Hopkins University Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2
EP1890691A2 (en) 2005-05-31 2008-02-27 Mylan Laboratories, Inc Compositions comrising nebivolol
US20090297496A1 (en) * 2005-09-08 2009-12-03 Childrens Hospital Medical Center Lysosomal Acid Lipase Therapy for NAFLD and Related Diseases
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
PL3279663T3 (pl) 2006-03-15 2022-01-10 The Brigham And Women's Hospital, Inc. Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
WO2007127965A1 (en) 2006-04-28 2007-11-08 Mayo Foundation For Medical Education And Research Treating glaucoma, cardiovascular diseases, and renal diseases
CA2659082A1 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP2147315B1 (en) 2007-04-18 2013-06-26 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
SG182821A1 (en) 2010-02-01 2012-08-30 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
US20110240043A1 (en) 2010-03-31 2011-10-06 The Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
RU2706366C2 (ru) * 2017-11-01 2019-11-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Пермская государственная фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО ПГФА Минздрава России) Способ отбора противовоспалительных средств с использованием рассчитанных энергий взаимодействия с ферментами циклооксигеназ 1 и 2
MA53650A (fr) 2018-09-19 2021-07-28 Modernatx Inc Lipides peg et leurs utilisations
EP3853305B1 (en) 2018-09-19 2024-10-02 ModernaTX, Inc. High-purity peg lipids and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4562155A (en) * 1983-05-19 1985-12-31 The Wistar Institute Of Anatomy And Biology Hybrid viral plasmid and microorganisms containing same
JPS63157980A (ja) 1986-12-22 1988-06-30 Chisso Corp プロスタグランジン合成酵素の安定化方法
JPH01228479A (ja) * 1988-03-10 1989-09-12 Meiji Milk Prod Co Ltd プロスタグランジンエンドペルオキシドシンテターゼをコードするｄｎａ
NZ256776A (en) * 1992-09-22 1997-10-24 Univ Rochester Transgenic mammalian cells containing a dna sequence expressing pghs-2
US6048850A (en) 1992-09-22 2000-04-11 Young; Donald A. Method of inhibiting prostaglandin synthesis in a human host
US5837479A (en) 1992-09-22 1998-11-17 Young; Donald A. Screening assays for inhibitors of mammalian prostaglandin H synthase-2
JPH06315798A (ja) * 1993-05-07 1994-11-15 Kobe Steel Ltd 高エネルギービーム溶接用裏当材

Also Published As

Publication number Publication date
ES2105611T3 (es) 1997-10-16
US5543297A (en) 1996-08-06
DK0675964T3 (da) 1997-09-15
DE69331340T2 (de) 2002-08-22
JPH08504584A (ja) 1996-05-21
HK1027471A1 (en) 2001-01-12
USRE39696E1 (en) 2007-06-19
EP1130110A2 (en) 2001-09-05
AU5690694A (en) 1994-07-19
JP3573743B2 (ja) 2004-10-06
CA2151231C (en) 2004-11-09
EP0736769B1 (en) 2001-12-12
DE69331340D1 (de) 2002-01-24
JP3608622B2 (ja) 2005-01-12
ATE155811T1 (de) 1997-08-15
GR3025111T3 (en) 1998-01-30
EP1130110A3 (en) 2005-02-23
EP0675964A1 (en) 1995-10-11
CA2151231A1 (en) 1994-07-07
DE69312513T2 (de) 1998-01-15
DE69312513D1 (de) 1997-08-28
JP2004081211A (ja) 2004-03-18
ATE210826T1 (de) 2001-12-15
EP0675964B1 (en) 1997-07-23
EP0736769A1 (en) 1996-10-09
WO1994014977A1 (en) 1994-07-07

Similar Documents

Publication Publication Date Title
ES2168436T3 (es) Ensayo para determinar la actividad de ciclooxigenasa 1.
MX9405383A (es) Imidazo(4,5-c) piridin-4-aminas.
AR246253A1 (es) Procedimiento para obtener derivados de dideshidro-vitamina d3.
ES2054649T3 (es) 2-aminotetralinas basicas substituidas.
AR063780A2 (es) Un anticuerpo aislado composicion farmaceutica que lo comprende y metodo para inhibir la actividad de y detectar una interleuquina
ES2054716T3 (es) Bis-naftalimidas, su obtencion y empleo.
ES2090217T3 (es) Laca fotosensible.
MX9205035A (es) Metodo nematocida
ES2064543T3 (es) Procedimiento para la determinacion de un analito.
ES2109223T3 (es) Reactivo para la determinacion coulombimetrica de agua.
ES2160892T3 (es) Uso de una mezcla de tensioactivos para inhibir la corrosion.
AR227654A1 (es) Formulaciones solidas que contienen feromonas
DK0731634T3 (da) Anatomisk og biologisk konserveringsmiddel og forbedret balsameringssammensætning og -fremgangsmåde
ES2153565T3 (es) Procedimiento y compuestos para la deteccion de analitos mediante medicion de la remanencia, y su utilizacion.
KR900700922A (ko) 수성 현상용액 및 포지티브-작용성 감광성 내식막 조성물 현상에 있어서의 이의 용도
ES2119001T3 (es) Determinacion de un analito en una muestra liquida.
ES2076320T3 (es) Adyuvante angiografico.
ATE361363T1 (de) Impfstoff, der peroxiredoxin enthält
AR004719A1 (es) Compuestos debisindolilmaleimidas con un punte n, n' y formulaciones farmaceuticas que los contienen, dichos compuestos son utiles comointermediarios para preparar otras bisindolilmaleimidas que poseen dicho puente n, n'
ES2174879T3 (es) Anticuerpos monoclonales que reconocen los receptores flk-2 y aislamiento de poblaciones de celulas madre primitivas hematopoyeticas.
ES2081119T3 (es) Sustratos cromogenicos para mejorar la deteccion en un ensayo basado en peroxidasa.
ES2168722T3 (es) Uso de una aleacion de molibdeno y/o wolframio para elementos de construccion que entran en contacto con masas fundidas de vidrio y/o de ceramica.
SE9604302L (sv) Testkit och förfarande
PT853476E (pt) Preparacao farmaceutica que contem nimesulide para uso topico
ES2150970T3 (es) Procedimiento y reactivo para la medida de la actividad del complemento.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 736769

Country of ref document: ES